Evidera

Evidera, a business within Pharmaceutical Product Development, LLC, (PPD), specializes in evidence, value, and access for biopharmaceutical and biotechnology products. The company, with over 30 years of experience, offers integrated scientific expertise and global operational capabilities to demonstrate real-world effectiveness, safety, and value from early development through loss of exclusivity.

Acquired by PPD in 2016, Evidera was originally established in 2013 under Symphony Technology Group after the acquisition of various health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Notable legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.

Evidera's focus on analytics and healthcare makes it a prominent player in the industry. However, the lack of available information on its last investment and investors hints at a potential shift in its financial strategy. Based in the United States, Evidera presents an intriguing opportunity for venture capitalists seeking exposure to the evolving landscape of evidence-based solutions within the biopharmaceutical and biotechnology sectors.